World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
153
Citations
112458
World Ranking
1021
National Ranking
580

Overview

Martin S. Tallman is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research is primarily situated within the field of Medicine, with a focus on hematology, molecular biology, genetics, public health, environmental and occupational health, and oncology.

The scientist's work extensively covers topics related to leukemia and hematopoietic diseases, including:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Retinoids in leukemia and cellular processes

Their publication record includes a substantial presence in journals such as Blood, Blood Advances, Leukemia & Lymphoma, Leukemia, and the Journal of Clinical Oncology. The most frequent venues for publications are:

  • Blood (56 publications)
  • Blood Advances (20 publications)
  • Leukemia & Lymphoma (12 publications)
  • Leukemia (8 publications)
  • Journal of Clinical Oncology (7 publications)

Martin S. Tallman has collaborated extensively with a consistent group of co-authors, including Mark R. Litzow, Ross L. Levine, Eytan M. Stein, Aaron D. Goldberg, and Selina M. Luger.

Some of the recent and notable papers that feature their contributions include:

  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN, 2022, Blood
  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, Blood
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis, 2020, Nature Genetics
  • NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study, 2020, Blood

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

    Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum

  • Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

    Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

    Jay P. Patel;Mithat Gönen;Maria E. Figueroa;Hugo Fernandez

  • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

    C. D. DiNardo;E. M. Stein;S. De Botton;G. J. Roboz

  • All-trans-Retinoic Acid in Acute Promyelocytic Leukemia

    Martin S. Tallman;Janet W. Andersen;Charles A. Schiffer;Frederick R. Appelbaum

  • Anthracycline Dose Intensification in Acute Myeloid Leukemia

    Hugo F. Fernandez;Zhuoxin Sun;Xiaopan Yao;Mark R. Litzow

  • United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

    Steven L. Soignet;Stanley R. Frankel;Dan Douer;Martin S. Tallman

  • Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

    Charles L. Bennett;Samuel M. Silver;Benjamin Djulbegovic;Athena T. Samaras

  • Drug therapy for acute myeloid leukemia.

    Martin S. Tallman;Martin S. Tallman;Martin S. Tallman;D. Gary Gilliland;D. Gary Gilliland;D. Gary Gilliland;Jacob M. Rowe;Jacob M. Rowe;Jacob M. Rowe

  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

    Adele K. Fielding;Susan M. Richards;Rajesh Chopra;Hillard M. Lazarus

  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero

  • Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

    Jacob M. Rowe;Georgina Buck;Alan Kenneth Burnett;Raj Chopra

  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

    Eytan M. Stein;Courtney Denton Dinardo;Daniel Aaron Pollyea;Amir Tahmasb Fathi

Frequent Co-Authors

Ross L. Levine
Ross L. Levine Memorial Sloan Kettering Cancer Center
Jacob M. Rowe
Jacob M. Rowe Technion – Israel Institute of Technology
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Richard Stone
Richard Stone Harvard University
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Richard A. Larson
Richard A. Larson University of Chicago
Omar Abdel-Wahab
Omar Abdel-Wahab Memorial Sloan Kettering Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Miguel A. Sanz
Miguel A. Sanz University of Valencia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online healthcare degrees is an excellent way to enter the medical field or enhance your career flexibility. Many prospective students are discovering online direct entry msn programs for non-nurses, which help those from non-nursing backgrounds quickly transition into advanced nursing roles without earning a second bachelor’s degree.

If you are concerned about a competitive admission process, you might want to look for what is the easiest nursing school to get into. Finding programs with higher acceptance rates can be a practical way to start your nursing journey sooner.

Healthcare offers a wide range of career paths—some of which do not require patient care. For example, people interested in healthcare administration might consider online medical billing and coding with financial aid as a flexible and affordable way to join the industry.

Lastly, if entrance exams are a barrier, look into a nursing school that don't require teas or HESI scores. These schools streamline the admissions process and open up more opportunities for aspiring healthcare professionals.

Best Scientists Citing Martin S. Tallman

Trending Scientists